Isidora Goyenechea 2800, las Condes Piso 42 755-0647 Santiago, Chile
Tel:(+56 2)29282200, Fax:(+56 2)29282200, E-mail:

Beatriz von Loebenstein

Associate Carey Isidora Goyenechea 2800, piso 43, Las Condes, Santiago, Chile.
tel.+56 2 2928 2229


Member of Carey’s Antitrust, Regulated Markets and Public Law Group. Her practice focuses on the areas of antitrust, administrative and regulatory law, public contacts, administrative disputes and public litigation.


Law, Universidad de Chile (Summa Cum Laude).

Activities and Memberships

Teaching Assistant of Administrative Law and Liability of the State, Universidad de Chile (Since 2012).


Chile (2016).


Spanish, English and German.

Recent Representative Experience

  • Cencosud on its defense regarding a lawsuit submitted by the National Economic Prosecutor (FNE) against Cencosud and two other supermarkets, for alleged collusion in fixing the resale price of chicken in the grocery store market.
  • AFP ProVida, a subsidiary of MetLife, on an administrative invalidation process against the resolutions that authorized the merger of ProVida with its parent company, MetLife, initiated by the Chilean Pensions Supervisor (Superintendencia de Pensiones). The invalidation process was initiated by order of the General Comptrollership of the Republic after the report of an Investigative Commission of the House of Representatives, to review the procedure that authorized the merger. Finally, it was decided not to invalidate the merger.
  • G.D. Searle (Pfizer’s subsidiary in Chile) regarding a lawsuit submitted by the FNE before the Antitrust Court for alleged abuse of dominant position. The FNE accused G.D. Searle of patent misuse, exceeding the exercise of legitimate intellectual property rights and sham litigation with the purpose of excluding competitors from using the active ingredient celecoxib (Celebrex).
  • G.D. Searle, a Pfizer company, on its successful defense in a claim filed by the National Economic Prosecutor’s Office for allegedly hindering free competition regarding its product Celebra (Celecoxib).
  • Metlife on the reorganization of its local entities which implied obtaining complex regulatory approvals. The counseling also included defending the legality of the deal, which was challenged by third parties.